On December 9, 2022, the launch meeting of Ruijin Parkinson's disease autologous stem cell therapy project were successfully held in Ruijin Hospital.

The autologous stem cell therapy project for Parkinson's disease launched this time will carry out a series of scientific research-clinical cooperation in strict compliance, including the establishment of iPSC libraries. It is reported that after the project starts the enrollment of patients, they need to go through an observation period of six months to one year. The first patients enrolled are planned to be between the ages of 50 and 80, with early patients preferred.

The launch of this project means that UniXell is deeply exploring the clinical application prospects of cell therapy drugs, and strives to work with partners to promote the innovation and development of stem cell therapy industry, relieve patients' pain as soon as possible, and benefit mankind.